MBIO RSI Chart
Last 7 days
23.1%
Last 30 days
-15.8%
Last 90 days
-75.2%
Trailing 12 Months
-92.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 1.1M | 0 | 0 | 0 |
2023 | 1.8M | 2.1M | 1.6M | 0 |
2022 | 367.0K | 310.0K | 894.0K | 1.4M |
2021 | 579.0K | 522.0K | 435.0K | 0 |
2020 | 1.4M | 1.1M | 885.0K | 708.0K |
2019 | 575.0K | 815.0K | 1.1M | 1.3M |
2018 | 560.5K | 573.5K | 567.5K | 569.0K |
2017 | 138.1K | 260.3K | 382.4K | 504.5K |
2016 | 0 | 0 | 0 | 16.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 02, 2024 | fortress biotech, inc. | acquired | - | - | 419,092 | - |
Jul 05, 2023 | zelefsky michael j | acquired | - | - | 7,246 | - |
Jul 05, 2023 | rosenwald lindsay a md | acquired | - | - | 7,246 | - |
Jul 05, 2023 | chill adam j. | acquired | - | - | 7,246 | - |
Jul 05, 2023 | herskowitz neil | acquired | - | - | 7,246 | - |
Jul 05, 2023 | weiss michael s | acquired | - | - | 7,246 | - |
Apr 24, 2023 | litchman manuel md | acquired | - | - | 5,000 | president and ceo |
Jan 06, 2023 | fortress biotech, inc. | acquired | - | - | 2,807,010 | - |
Sep 13, 2022 | rosenwald lindsay a md | bought | 2,582 | 0.5164 | 5,000 | - |
Sep 13, 2022 | litchman manuel md | bought | 2,582 | 0.5164 | 5,000 | - |
Which funds bought or sold MBIO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | Clear Point Advisors Inc. | unchanged | - | - | 1.00 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 10,512 | 10,512 | -% |
May 15, 2024 | Royal Bank of Canada | added | 293 | 1,000 | 1,000 | -% |
May 15, 2024 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 14.00 | 14.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 24.86 | -327 | 8,268 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | reduced | -51.81 | -369,881 | 218,400 | -% |
May 15, 2024 | Squarepoint Ops LLC | new | - | 15,543 | 15,543 | -% |
May 15, 2024 | PACIFIC CAPITAL WEALTH ADVISORS, INC | unchanged | - | -2.00 | 6.00 | -% |
May 15, 2024 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | sold off | -100 | -12.00 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -31.28 | -134 | 151 | -% |
Unveiling Mustang Bio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Mustang Bio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Mustang Bio Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | -70.3% | 41.00 | 138 | 429 | 453 | 560 | 669 | 77.00 | 73.00 | 75.00 | 85.00 | 134 | 141 | 162 | 142 | 263 | 318 | 406 | 387 | 152 | 138 | 138 |
Operating Expenses | -49.2% | 5,231 | 10,307 | 13,891 | 16,321 | 19,432 | 18,848 | 18,241 | 19,638 | 17,077 | 14,440 | 15,087 | 20,738 | 10,427 | 14,121 | 11,520 | 15,923 | 9,996 | 10,212 | 9,754 | 11,875 | 7,656 |
S&GA Expenses | -100.0% | - | 2,131 | 3,055 | 2,321 | 2,395 | 3,389 | 3,077 | 3,349 | 2,364 | 2,538 | 3,469 | 2,405 | 2,153 | 2,991 | 1,956 | 2,050 | 1,987 | 3,189 | 2,344 | 1,651 | 1,340 |
Interest Expenses | -100.0% | - | 4.00 | 2,932 | 1,176 | 1,160 | 1,034 | 935 | 230 | 3.00 | 4.00 | 4.00 | -2,313 | 2,687 | 619 | 600 | 604 | 578 | 574 | 11.00 | 8.00 | - |
Net Income | 48.4% | -5,191 | -10,058 | -16,235 | -16,693 | -19,634 | -18,997 | -19,099 | -19,795 | -17,005 | -14,359 | -14,957 | -20,608 | -12,952 | -14,598 | -11,857 | -16,209 | -10,168 | -10,399 | -9,613 | -11,770 | -7,518 |
Net Income Margin | 4.6% | -37.79* | -39.63* | -33.90* | -42.31* | -56.22* | -87.18* | -244.99* | -194.03* | -153.86* | -120.45* | -109.01* | -84.77* | -62.84* | -46.80* | -35.40* | -36.73* | -38.73* | -48.22* | -59.12* | -53.89* | -60.78* |
Free Cashflow | 55.5% | -5,351 | -12,023 | -12,426 | -17,808 | -15,384 | -16,892 | -17,881 | -17,623 | -11,749 | -13,786 | -16,038 | -10,172 | -10,262 | -8,132 | -10,678 | -10,381 | -9,329 | -9,434 | -6,782 | -6,827 | -4,948 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -17.8% | 15.00 | 18.00 | 21.00 | 29.00 | 74.00 | 92.00 | 109 | 122 | 137 | 125 | 135 | 143 | 142 | 110 | 86.00 | 97.00 | 69.00 | 73.00 | 84.00 | 93.00 | 50.00 |
Current Assets | -18.6% | 9.00 | 11.00 | 14.00 | 23.00 | 61.00 | 79.00 | 94.00 | 109 | 124 | 112 | 122 | 131 | 131 | 100 | 76.00 | 86.00 | 58.00 | 63.00 | 74.00 | 83.00 | 42.00 |
Cash Equivalents | -72.5% | 2.00 | 6.00 | 10.00 | 15.00 | 58.00 | 76.00 | 91.00 | 107 | 122 | 111 | 121 | 130 | 129 | 99.00 | 75.00 | 85.00 | 57.00 | 62.00 | 73.00 | 83.00 | 36.00 |
Net PPE | -8.8% | 3.00 | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | 10.9% | 20.00 | 18.00 | 17.00 | 15.00 | 44.00 | 46.00 | 45.00 | 40.00 | 40.00 | 13.00 | 12.00 | 8.00 | 8.00 | 11.00 | 10.00 | 26.00 | 23.00 | 22.00 | 21.00 | 21.00 | 22.00 |
Current Liabilities | 13.4% | 17.00 | 15.00 | 14.00 | 13.00 | 13.00 | 15.00 | 14.00 | 11.00 | 11.00 | 11.00 | 10.00 | 6.00 | 7.00 | 10.00 | 8.00 | 15.00 | 10.00 | 8.00 | 6.00 | 6.00 | 7.00 |
Short Term Borrowings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.00 | 3.00 | 1.00 | - | - | - |
Shareholder's Equity | -4118.7% | -4.94 | 0.00 | 4.00 | 14.00 | 30.00 | 46.00 | 64.00 | 82.00 | 97.00 | 112 | 122 | 135 | 133 | 98.00 | 76.00 | 71.00 | 46.00 | 52.00 | 62.00 | 71.00 | 28.00 |
Retained Earnings | -1.4% | -386 | -381 | -372 | -362 | -346 | -329 | -309 | -290 | -271 | -251 | -231 | -214 | -200 | -185 | -164 | -151 | -137 | -125 | -109 | -99.08 | -88.68 |
Additional Paid-In Capital | 0.2% | 381 | 381 | 376 | 376 | 376 | 375 | 374 | 373 | 369 | 360 | 354 | 350 | 334 | 276 | 241 | 223 | 183 | 172 | 172 | 171 | 117 |
Shares Outstanding | 30.8% | 11.00 | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 6.00 | 6.00 | 6.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 |
Float | - | - | - | - | 39.00 | - | - | - | 49.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 26.6% | -5,321 | -7,254 | -12,023 | -12,392 | -17,808 | -15,289 | -15,913 | -17,575 | -16,289 | -14,703 | -11,289 | -12,095 | -15,580 | -9,475 | -10,124 | -7,568 | -10,152 | -9,490 | -8,830 | -8,778 | -6,483 |
Share Based Compensation | -59.6% | 76.00 | 188 | 100 | 45.00 | 235 | 473 | 496 | 650 | 664 | 881 | 884 | 547 | 996 | 619 | 606 | 957 | 805 | 490 | 1,120 | 622 | 432 |
Cashflow From Investing | 100.0% | - | -30.00 | 5,950 | -34.00 | - | -420 | -892 | -306 | -1,334 | -1,477 | -990 | -2,441 | -458 | -1,464 | -1,608 | -814 | -526 | -1,391 | -899 | 4,198 | 12,001 |
Cashflow From Financing | -98.8% | 49.00 | 3,956 | 250 | -30,287 | - | 1.00 | 800 | 3,034 | 30,221 | 4,919 | 3,235 | 15,088 | 47,605 | 33,492 | 1,622 | 37,929 | 5,079 | - | -111 | 51,614 | 13,613 |
Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 3,804 | $ 14,000 |
General and administrative | 1,427 | 2,321 |
Total operating expenses | 5,231 | 16,321 |
Loss from operations | (5,231) | (16,321) |
Other income (expense) | ||
Other income | 0 | 351 |
Interest income | 41 | 453 |
Interest expense | (1) | (1,176) |
Total other income (expense) | 40 | (372) |
Net Loss | $ (5,191) | $ (16,693) |
Net loss per common share outstanding, basic | $ (0.46) | $ (2.06) |
Net loss per common share outstanding, diluted | $ (0.46) | $ (2.06) |
Weighted average number of common shares outstanding, basic | 11,253,767 | 8,093,662 |
Weighted average number of common shares outstanding, diluted | 11,253,767 | 8,093,662 |
Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 1,337 | $ 6,234 |
Other receivables | 6,738 | 3,879 |
Prepaid expenses and other current assets | 1,165 | 1,233 |
Total current assets | 9,240 | 11,346 |
Property, plant and equipment, net | 2,962 | 3,247 |
Restricted cash | 375 | 750 |
Other assets | 530 | 833 |
Operating lease right-of-use asset, net | 1,485 | 1,566 |
Total Assets | 14,592 | 17,742 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 15,014 | 14,017 |
Operating lease liabilities - short-term | 570 | 520 |
Total current liabilities | 17,438 | 15,371 |
Deferred income | 270 | 270 |
Operating lease liabilities - long-term | 1,827 | 1,978 |
Total Liabilities | 19,535 | 17,619 |
Commitments and Contingencies (Note 11) | ||
Stockholders' Equity | ||
Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 0 | 0 |
Common stock issuable, zero and 419,089 shares as of March 31, 2024 and December 31, 2023, respectively | 0 | 591 |
Additional paid-in capital | 381,218 | 380,502 |
Accumulated deficit | (386,162) | (380,971) |
Total Stockholders' Equity | (4,943) | 123 |
Total Liabilities and Stockholders' Equity | 14,592 | 17,742 |
Related Party [Member] | ||
Current Liabilities: | ||
Payables and accrued expenses - related party | 1,854 | 834 |
Class A common shares | ||
Stockholders' Equity | ||
Common stock ($0.0001 par value), 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively | 0 | 0 |
Common shares | ||
Stockholders' Equity | ||
Common stock ($0.0001 par value), 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively | $ 1 | $ 1 |